52 results
10-K
2023 FY
EX-31.1
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have
10-K
2023 FY
EX-10.22
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
act of dishonesty, fraud, or misrepresentation in relation to Executive’s duties to the Company which act is materially and demonstrably injurious
10-K
EX-10.23
pa4th80y66y 839
7 Mar 24
Annual report
4:05pm
10-K
EX-31.2
wlmpk7tdp494szzp1
7 Mar 24
Annual report
4:05pm
10-K
h0rc9p
7 Mar 24
Annual report
4:05pm
10-Q
EX-31.1
rj9qyhi
1 Nov 23
Quarterly report
4:05pm
10-Q
EX-31.2
qogwwjhzv67fsf
1 Nov 23
Quarterly report
4:05pm
S-8
EX-99.1
94j4upikq8kkz7ahxg3
19 Sep 23
Registration of securities for employees
9:57pm
S-8
EX-99.3
gfim2
19 Sep 23
Registration of securities for employees
9:57pm
8-K
EX-3.2
yvdi4gpey6ga3
19 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
424B4
svott1n cry55v
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
EX-1.1
r9jf osdouk8ewkkj
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
hunt2k3nhq4ep4s t9
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-10.6
yd4tk
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.1
ya9ryoz
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.4
20xcy u4wbkz
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.11
t26vb4 h2afrq2
25 Aug 23
IPO registration
5:03pm